The Rights Plan is effective immediately and will expire on March 12, 2026. ACELYRIN stockholders do not need to take any further action at this time.
Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...
Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of ...
In a report released today, Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Alumis Inc. (ALMS – Research Report), with a price ...
Acelyrin has declined a surprise offer from Concentra Biosciences, and is instead p | Acelyrin consulted with independent ...
Alumis (ALMS) announced positive 52-week data from the open-label extension, OLE, of its Phase 2 STRIDE clinical trial evaluating ESK-001 in ...
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to ...
HC Wainwright reissued their buy rating on shares of Alumis (NASDAQ:ALMS – Free Report) in a report published on Monday,Benzinga reports. They currently have a $19.00 price objective on the stock. A ...
Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback